Abstract
Granular non-fibrillar aggregates (GNAs) are identified as possible toxic species in Alzheimer's disease. GNAs form on the surface of negatively charged biological membranes and as a consequence of an acidic environment, off the polymerization pathway at neutral pH. Aβ (1-40) GNAs disturb the bilayer structure of model membranes and seem to be more toxic to cells with negatively charged membranes (consequence of chronic pre-apoptosis). GNAs may be relevant in physiological situations associated to Alzheimer's disease: a local acidic pH at the cell surface (consequence of lipid oxidation or other cell insults) and acidification as a consequence of vascular events causing hypoxia. Together with previous descriptions of granular aggregates with poly-glutamine peptides related to Huntington's disease and the SH3 domain of PI3, GNAs related to Alzheimer's disease are a further example of a possible common aggregation and toxicity mechanism in conformational diseases. GNAs may represent a new pharmacological target in Alzheimer's disease.
Keywords: Alzheimer’s, amyloid, membranes, non-fibrillar, pH, Electrophoresis, phosphatidylserine, lipid oxidation
Current Alzheimer Research
Title:Granular Non-Fibrillar Aggregates and Toxicity in Alzheimer’s Disease
Volume: 9 Issue: 8
Author(s): Nuria Benseny-Cases, Oxana Klementieva, Jan Maly and Josep Cladera
Affiliation:
Keywords: Alzheimer’s, amyloid, membranes, non-fibrillar, pH, Electrophoresis, phosphatidylserine, lipid oxidation
Abstract: Granular non-fibrillar aggregates (GNAs) are identified as possible toxic species in Alzheimer's disease. GNAs form on the surface of negatively charged biological membranes and as a consequence of an acidic environment, off the polymerization pathway at neutral pH. Aβ (1-40) GNAs disturb the bilayer structure of model membranes and seem to be more toxic to cells with negatively charged membranes (consequence of chronic pre-apoptosis). GNAs may be relevant in physiological situations associated to Alzheimer's disease: a local acidic pH at the cell surface (consequence of lipid oxidation or other cell insults) and acidification as a consequence of vascular events causing hypoxia. Together with previous descriptions of granular aggregates with poly-glutamine peptides related to Huntington's disease and the SH3 domain of PI3, GNAs related to Alzheimer's disease are a further example of a possible common aggregation and toxicity mechanism in conformational diseases. GNAs may represent a new pharmacological target in Alzheimer's disease.
Export Options
About this article
Cite this article as:
Benseny-Cases Nuria, Klementieva Oxana, Maly Jan and Cladera Josep, Granular Non-Fibrillar Aggregates and Toxicity in Alzheimer’s Disease, Current Alzheimer Research 2012; 9 (8) . https://dx.doi.org/10.2174/156720512803251129
DOI https://dx.doi.org/10.2174/156720512803251129 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology An Up-date of Olive Oil Phenols in Inflammation and Cancer: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry Pathophysiology of Blood-Spinal Cord Barrier in Traumatic Injury and Repair
Current Pharmaceutical Design Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Bacopa monnieri Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice
Central Nervous System Agents in Medicinal Chemistry Gene Expression-Based Pharmacodynamic Biomarkers: The Beginning of a New Era in Biomarker-Driven Anti-Tumor Drug Development
Current Molecular Medicine Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Application of dsRNA in Cancer Immunotherapy: Current Status and Future Trends
Anti-Cancer Agents in Medicinal Chemistry Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers
Current Cancer Drug Targets Role of Mu and Delta Opioid Receptors in Alcohol Drinking Behaviour
Current Drug Abuse Reviews New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design Cytotoxic Effect of the Red Beetroot (Beta vulgaris L.) Extract Compared to Doxorubicin (Adriamycin) in the Human Prostate (PC-3) and Breast (MCF-7) Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Recent Developments on the Use of Nanomaterials for the Treatment of Epilepsy
Mini-Reviews in Medicinal Chemistry The Coronin Family and Human Disease
Current Protein & Peptide Science Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy